Association details:
Evidence Level:
Sensitive: C3 – Early Trials

PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy

All patients were stage IV NSCLC including 5 females with adenocarcinoma and 1 male with squamous carcinoma...Acquired PIK3CA mutations, PTEN loss were detected after progression on EGFR TKIs in all patients, with patient 4 harboring both PIK3CA mutation and PTEN loss. Four patients were treated with osimertinib 80 mg and the rest gefitinib 250 mg. The dose of everolimus was 5 mg daily in all patients. According to RECISIT 1.1, six patients achieved stable disease (SD)...Depiction of clinicopathological characteristics, combination therapy, major mutations prior to combination therapy of six patients...